Ocular Therapeutix, Inc. (OCUL)
9.49
+0.54
(+5.97%)
USD |
NASDAQ |
Feb 25, 16:00
9.51
+0.02
(+0.21%)
After-Hours: 17:23
Ocular Therapeutix Research and Development Expense (Quarterly) : 50.80M for Dec. 31, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Regeneron Pharmaceuticals, Inc. | 1.481B |
| Boston Scientific Corp. | 569.00M |
| Alnylam Pharmaceuticals, Inc. | 372.22M |
| EyePoint Plc | 47.75M |
| Vertex Pharmaceuticals, Inc. | 973.70M |